LACKNER MARK (Chief Scientific Officer) sold 2.3% of their position (4.41K shares) of ZENTALIS PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $13.8K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 1/3/2025ACC: 0001725160-25-000002
Officer· Chief Scientific Officer
Since Dec 2023
-4.41K
Net shares
Net seller
$13.8K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
4.41K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−4.41K
Price / share
$3.12
Trade value
$13.76K
% of position
2.3%
1/2/2025
195.73K→191.32K
Total
Net shares
−4.41K
Net value
-$13.76K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/2/2025 | S · Sale | −4.41K | $3.12 | $13.76K | 2.3% | 195.73K | 191.32K |
| Total | −4.41K | -$13.76K | ||||||
Derivative Transactions0
No derivative transactions reported